BrainsWay Ltd. (NASDAQ:BWAY) Short Interest Update

BrainsWay Ltd. (NASDAQ:BWAY) saw a large drop in short interest in the month of February. As of February 28th, there was short interest totalling 55,300 shares, a drop of 31.0% from the February 13th total of 80,200 shares. Based on an average trading volume of 65,600 shares, the days-to-cover ratio is currently 0.8 days. Currently, 0.4% of the shares of the company are short sold.

BrainsWay Price Performance

BrainsWay stock opened at $10.21 on Friday. The stock has a market capitalization of $192.22 million, a P/E ratio of 102.11 and a beta of 1.29. BrainsWay has a 12-month low of $4.61 and a 12-month high of $11.79. The firm’s 50-day moving average is $10.26 and its two-hundred day moving average is $9.62.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and issued a $16.00 price objective on shares of BrainsWay in a research report on Wednesday.

Institutional Investors Weigh In On BrainsWay

A number of hedge funds and other institutional investors have recently made changes to their positions in BWAY. Lazard Asset Management LLC purchased a new stake in BrainsWay during the fourth quarter valued at about $44,000. JPMorgan Chase & Co. boosted its stake in BrainsWay by 316.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 14,769 shares of the company’s stock valued at $136,000 after acquiring an additional 11,221 shares during the last quarter. Sei Investments Co. bought a new stake in BrainsWay in the fourth quarter valued at about $149,000. Cubist Systematic Strategies LLC increased its holdings in shares of BrainsWay by 14.6% in the 4th quarter. Cubist Systematic Strategies LLC now owns 19,228 shares of the company’s stock valued at $181,000 after acquiring an additional 2,446 shares during the last quarter. Finally, Rhumbline Advisers raised its holdings in shares of BrainsWay by 10.8% during the fourth quarter. Rhumbline Advisers now owns 21,966 shares of the company’s stock worth $207,000 after purchasing an additional 2,144 shares during the period. Hedge funds and other institutional investors own 30.11% of the company’s stock.

About BrainsWay

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.